Inventiva SA · EURONEXT:IVA
Inventiva SA — Jefferies Virtual Healthcare Conference 2020
10 slides from Inventiva SA's conference presentation, June 2020
Slide 1: Developing breakthrough therapies in NASH and MPS
Developing breakthrough therapies in NASH and MPS Corporate Presentation June 2020
Slide 2: Disclaimer
DISCLAIMER This document has been prepared by Inventiva (the "Company") solely for the purpose of this presentation. This document is not to be reproduced by any person nor is it to be distributed.This presentation includes only summary information and does not purport to be comprehensive. Any infor
Slide 3: Inventiva: highlights
Inventiva: highlights Clinical stage biotech with focus on oral small molecules for high unmet need in fibrosis, lysosomal storage disorders and oncology Two unencumbered late stage assets in two high value indications – Lanifibranor – only pan-PPAR agonist in clinical development for NASH, Phase II
Slide 4: Lanifibranor: the only pan-PPAR agonist in clinical development for the treatment of NASH
Lanifibranor: the only pan-PPAR agonist in clinical development for the treatment of NASH Moderate and balanced pan-PPAR agonist activity (PPAR, PPAR and PPAR) with differentiated chemical structure Once daily oral administration Efficacy demonstrated on insulin-sensitivity, dyslipidemia, steatos
Slide 5: PPAR efficacy is well established in NASH
PPAR efficacy is well established in NASH PPAR activation by pioglitazone improves steatosis, ballooning, inflammation and metabolic markers in NASH patients after 6 months or 18 months of treatment Belfort NASH study Cusi NASH study 6 month treatment 18 month treatment Pioglitazone (PPAR) Placeb
Slide 6: PPAR activity can also be reinforced by PPAR efficacy
PPAR activity can also be reinforced by PPAR efficacy Anti-inflammatory effects of lanifibranor mediated through PPAR activation reported in preclinical models Seladelpar (potent selective PPAR) phase IIb trial reported encouraging results in the 152 patients having paired biopsies at entry
Slide 7: NATIVE: a phase III enabling study
NATIVE: a phase III enabling study Trial design Principal investigators Randomisation Prof. Francque (Antwerp University, Belgium) and Prof. Abdelmalek 1/1/1, stratification on T2DM patients (Duke University, USA) Study powered with 75 patients per group Inclusion criteria Central reading
Slide 8: Lanifibranor: differentiated potential compared to phase III programs to address all features of NASH
Lanifibranor: differentiated potential compared to phase III programs to address all features of NASH in safe and efficacious manner Lanifibranor Ocaliva Cenicriviroc Resmetirom Aramchol Insulino- resistance Steatosis Necro- Unclear inflammation Fibrosis Unclear Corporate Presentation | 2020 Non-con
Slide 9: Recent and upcoming key milestones
Recent and upcoming key milestones Lanifibranor Results: phase IIb NASH - June 2020 Odiparcil Positive results of the phase IIa in MPS VI Launch of a Phase Ib/II clinical trial of odiparcil in a pediatric population with MPS VI Initiate a Phase IIa extension study in patients who completed t
Slide 10: Contacts
Contacts Inventiva Brunswick Westwicke, an ICR Company Frédéric Cren Yannick Tetzlaff / Tristan Roquet Montégon Patricia L. Bank / Aude Lepreux CEO Investor relations Media relations [email protected] [email protected] [email protected] +33 (0)3 80 44 75 00 + 33 1 53 96 83 8
Inventiva — Jefferies Virtual Healthcare Conference 2020 on 6ix